Enanta loses patent infringement action against Pfizer as UPC rules patent invalid
ENTA•The UPC ruled that Enanta’s patent was invalid and its infringement action against Pfizer was unfounded, according to a securities filing.
1. UPC ruling
Enanta Pharmaceuticals said in a securities filing that the UPC ruled its ’265 patent invalid and determined its patent infringement action against Pfizer was unfounded.
